ClinicalTrials.gg
CompletedNCT05649917Updated Nov 6, 2026Results posted

SPR PNS for Chronic Shoulder Pain

An observational study in Shoulder Pain, Shoulder Injuries and Shoulder Arthritis, sponsored by International Spine, Pain and Performance Center. Completed at 2 sites in United States. Open to participants aged 21 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by International Spine, Pain and Performance Center · Observational

How we know

Updated Nov 6, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
3
Ages
21 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.

Enrollment
24th of 24
3 · median 65
Started
2022
with 8 others
Observational
24 of 146
6 open now
Registered
123rd of 146
by date

Among the 146 studies in Shoulder Pain with a site in United States, this one is the 24th largest by enrollment of the 24 observational ones that give a count, is one of 9 that started in 2022, is one of 24 observational ones, and was the 123rd registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 21 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Shoulder Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to gather post-market data regarding the effectiveness of the SPRINT Peripheral Nerve Stimulation (PNS) System for the treatment of chronic shoulder pain due to chronic degenerative changes of your shoulder. The System delivers mild electrical stimulation to the muscles in your shoulder. The System includes up to two leads (small wires) that are placed through your skin into your shoulder. The leads attach to a device worn on your body that deliver stimulation (called a Stimulator). The device is cleared by the FDA for up to 60 days of use for the relief of chronic or acute pain.

Read the detailed description

Background

Chronic degenerative changes in the shoulder are a frequent source of debilitating chronic pain. In particular, osteoarthritis of the shoulder has been estimated to affect up to 32.8% of the adult population over the age of 60, and OA in general is one of the most frequent causes of disability in the United States.1 OA impacts the quality of life of tens of millions of Americans and carries a significant economic burden of over $60 billion in the U.S. each year.2

Degenerative joint disease in the shoulder is commonly managed with physical therapy and over-the-counter medications, but these modalities can be insufficient for pain management as degeneration progresses.3 Corticosteroid injections, radiofrequency ablations, and even partial or total shoulder arthroplasty are used to treat advanced cases3, and these interventions often either have limited long-term effectiveness or are associated with significant invasiveness or other side effects and complications.

Peripheral nerve stimulation (PNS) is a neuromodulatory technique that seeks to provide pain relief through stimulation of the nerves that innervate the shoulder (e.g., the suprascapular nerve and axillary nerve). A novel, 60-day percutaneous PNS system that is FDA-cleared has shown effectiveness for chronic shoulder pain following stroke and shoulder impingement syndrome4-15, and has demonstrated the potential to provide sustained relief following the short-term, 60-day treatment.8, 15-18 The mechanism of action of neuropathic pain in osteoarthritis is proposed to be via peripheral sensitization (e.g., axillary and suprascapular nerves) that leads to subsequent upstream hypersensitization of the central nervous system; the proposed mechanism of long-term pain relief with 60-day PNS via reconditioning of the CNS to reverse hypersensitization therefore suggests that the treatment may be effective for degenerative shoulder including OA.19, 20 However, no study has prospectively evaluated the use of 60-day, percutaneous PNS for the treatment of debilitating pain associated with degenerative changes in the shoulder. The goal of this study is therefore to collect data on the use of 60-day PNS for the treatment of chronic pain associated with degenerative shoulder.

Objectives

The study objective is to gather post-market data regarding the effectiveness of the SPRINT PNS System for the treatment of chronic shoulder pain due to degenerative changes of the shoulder.

03

Conditions studied

  • Shoulder Pain
  • Shoulder Injuries
  • Shoulder Arthritis

Keywords

  • Peripheral Nerve Stimulation
  • Shoulder Pain
  • Shoulder Injuries
04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will enroll up to 20 patients with pain due to degenerative changes in the shoulder scheduled for commercial placement of the SPRINT PNS System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 21 years old
  • Diagnosed with degenerative changes within the shoulder complex
  • Scheduled for a commercial SPRINT PNS procedure
  • Shoulder pain score at baseline >5 as demonstrated by PROMIS 29
  • Able to understand and willing to take part in study and comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • No shoulder pain at rest
  • Pain exclusively in the anterior aspect of the shoulder
  • Confounding conditions such as cervical radiculopathy, inflammatory arthritis, complete rotator cuff tear, or ipsilateral shoulder surgery in the past one year
  • Daily opioid use >90 m morphine equivalent at any point in the past month
  • Opioids for any condition other than shoulder pain
  • Deep brain stimulation (DBS) system, implanted active cardiac implant (e.g. pacemaker or defibrillator), or any other implantable neuro-stimulator whose stimulus current pathway may overlap with the SPRINT system.
  • Any other condition that may interfere with the ability to participate in a clinical trial (e.g. anatomy that may interfere with lead placement, nerve damage, compromised immune system, uncontrolled DM) as determined by the Investigator
  • Vulnerable populations (e.g., prisoners, minors, students, employees)
  • Workers Compensation
  • Pregnant
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
3 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain Intensity

    All subjects completed PROMIS-29 Profile v.21 and BPI-9 at Baseline and at 3-months after the start of treatment. Average pain intensity is measured using the Brief Pain Inventory--Short form Question #9 (BPI-9). BPI-9 uses a 0-10 numeric rating scale across seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance). Average pain interference was calculated utilizing PROMIS-29. The average score for the PROMIS-29 pain interference assessment for the general population in the United States is 50, with a standard deviation of 10. The raw score for pain interference ranges from 4 to 20. Higher scores on PROMIS measures indicated more of the concept being measured. For example, a score of 60 is one standard deviation above the average population.

    Time frame: 3 months

Secondary outcomes

  1. Percent Change in Pain Interference Score

    Changes in average pain interference are measured using PROMIS-29 v2.1, Pain Interference domain. This domain includes four questions intended to capture a patient's ability to function in daily life living with pain. Questions assess pain interference with: day to day activities, work around the home, social activities, and household chores. Patients report the degree of pain interference via five-point Likert scale, from "Not at all" to "Very much." A positive change would indicate an increase in pain interference in activities of daily living from baseline, while a negative change would indicate a decrease in pain interference.

    Time frame: 3 months

  2. Changes in Shoulder Function

    Shoulder function is measured using the Western Ontario Arthritis of the Shoulder (WOOS) index. The WOOS index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis.

    Time frame: 1 year

  3. Changes in Shoulder Range of Motion

    Shoulder range of motion is measured as degrees of active range of motion (flexion, abduction, internal rotation, and external rotation) based on physical examination.

    Time frame: 1 year

07

Results

Posted Nov 6, 2026

Participant flow

Participants were recruited who received the SPR PNS device commercially at our pain practice between June 2022 and June 2024. The first participant was enrolled on July 12, 2022 and the final participant was enrolled on September 27, 2023.

Participant flow — Overall Study
MilestoneSPR PNS
Started2
Completed1
Not completed1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain Intensity

All subjects completed PROMIS-29 Profile v.21 and BPI-9 at Baseline and at 3-months after the start of treatment. Average pain intensity is measured using the Brief Pain Inventory--Short form Question #9 (BPI-9). BPI-9 uses a 0-10 numeric rating scale across seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance). Average pain interference was calculated utilizing PROMIS-29. The average score for the PROMIS-29 pain interference assessment for the general population in the United States is 50, with a standard deviation of 10. The raw score for pain interference ranges from 4 to 20. Higher scores on PROMIS measures indicated more of the concept being measured. For example, a score of 60 is one standard deviation above the average population.

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain Intensity
ParticipantsSPR PNS
Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain Intensity1
SecondaryPercent Change in Pain Interference Score

Changes in average pain interference are measured using PROMIS-29 v2.1, Pain Interference domain. This domain includes four questions intended to capture a patient's ability to function in daily life living with pain. Questions assess pain interference with: day to day activities, work around the home, social activities, and household chores. Patients report the degree of pain interference via five-point Likert scale, from "Not at all" to "Very much." A positive change would indicate an increase in pain interference in activities of daily living from baseline, while a negative change would indicate a decrease in pain interference.

Time frame:
3 months
Reported as:
Mean · percent change
Percent Change in Pain Interference Score
percent changeSPR PNS
Percent Change in Pain Interference Score-18.4 (-26.3 to -10.5)
SecondaryChanges in Shoulder Function

Shoulder function is measured using the Western Ontario Arthritis of the Shoulder (WOOS) index. The WOOS index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis.

Time frame:
1 year

Results for this outcome have not been posted.

SecondaryChanges in Shoulder Range of Motion

Shoulder range of motion is measured as degrees of active range of motion (flexion, abduction, internal rotation, and external rotation) based on physical examination.

Time frame:
1 year

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPR PNS———

Baseline characteristics

Subjects who consented and received the SPR PNS device for chronic shoulder pain.

Age, Continuous
Age, Continuous(years)SPR PNS
Mean83.5 (78 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)SPR PNS
Female2
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SPR PNS
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SPR PNS
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
Current Employment Status
Current Employment Status(Participants)SPR PNS
Retired (not due to health)2
Currently Working0
On leave of absence0
Homemaker0
Unemployed0
Student0
Disabled and/or retired because of pain0
Tobaco History
Tobaco History(Participants)SPR PNS
Never Smoked2
Past Smoker0
Current Smoker0
08

Study locations

2 sites
09

References and documents

Publications

  • Chillemi C, Franceschini V. Shoulder osteoarthritis. Arthritis. 2013;2013:370231. doi: 10.1155/2013/370231. Epub 2013 Jan 10. PubMed 23365745 ↗
  • Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004 Oct;(427 Suppl):S6-15. doi: 10.1097/01.blo.0000143938.30681.9d. PubMed 15480076 ↗
  • Millett PJ, Gobezie R, Boykin RE. Shoulder osteoarthritis: diagnosis and management. Am Fam Physician. 2008 Sep 1;78(5):605-11. PubMed 18788237 ↗
  • Chae J, Yu D, Walker M. Percutaneous, intramuscular neuromuscular electrical stimulation for the treatment of shoulder subluxation and pain in chronic hemiplegia: a case report. Am J Phys Med Rehabil. 2001 Apr;80(4):296-301. doi: 10.1097/00002060-200104000-00014. PubMed 11277137 ↗
  • Yu DT, Chae J, Walker ME, Fang ZP. Percutaneous intramuscular neuromuscular electric stimulation for the treatment of shoulder subluxation and pain in patients with chronic hemiplegia: a pilot study. Arch Phys Med Rehabil. 2001 Jan;82(1):20-5. doi: 10.1053/apmr.2001.18666. PubMed 11239281 ↗
  • Renzenbrink GJ, IJzerman MJ. Percutaneous neuromuscular electrical stimulation (P-NMES) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of life. Clin Rehabil. 2004 Jun;18(4):359-65. doi: 10.1191/0269215504cr759oa. PubMed 15180118 ↗
  • Yu DT, Chae J, Walker ME, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Frost FS, Grill JH, Feldstein M, Fang ZP. Intramuscular neuromuscular electric stimulation for poststroke shoulder pain: a multicenter randomized clinical trial. Arch Phys Med Rehabil. 2004 May;85(5):695-704. doi: 10.1016/j.apmr.2003.07.015. PubMed 15129391 ↗
  • Chae J, Yu DT, Walker ME, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Frost FS, Grill JH, Fang ZP. Intramuscular electrical stimulation for hemiplegic shoulder pain: a 12-month follow-up of a multiple-center, randomized clinical trial. Am J Phys Med Rehabil. 2005 Nov;84(11):832-42. doi: 10.1097/01.phm.0000184154.01880.72. PubMed 16244520 ↗
  • Chae J, Ng A, Yu DT, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Fang ZP. Intramuscular electrical stimulation for shoulder pain in hemiplegia: does time from stroke onset predict treatment success? Neurorehabil Neural Repair. 2007 Nov-Dec;21(6):561-7. doi: 10.1177/1545968306298412. Epub 2007 Mar 16. PubMed 17369520 ↗
  • Wilson RD, Bennett ME, Lechman TE, Stager KW, Chae J. Single-lead percutaneous peripheral nerve stimulation for the treatment of hemiplegic shoulder pain: a case report. Arch Phys Med Rehabil. 2011 May;92(5):837-40. doi: 10.1016/j.apmr.2010.11.003. PubMed 21530732 ↗
  • Wilson RD, Harris MA, Bennett ME, Chae J. Single-lead percutaneous peripheral nerve stimulation for the treatment of shoulder pain from subacromial impingement syndrome. PM R. 2012 Aug;4(8):624-8. doi: 10.1016/j.pmrj.2012.03.002. PubMed 22920317 ↗
  • Chae J, Wilson RD, Bennett ME, Lechman TE, Stager KW. Single-lead percutaneous peripheral nerve stimulation for the treatment of hemiplegic shoulder pain: a case series. Pain Pract. 2013 Jan;13(1):59-67. doi: 10.1111/j.1533-2500.2012.00541.x. Epub 2012 Mar 26. PubMed 22448759 ↗
  • Wilson RD, Gunzler DD, Bennett ME, Chae J. Peripheral nerve stimulation compared with usual care for pain relief of hemiplegic shoulder pain: a randomized controlled trial. Am J Phys Med Rehabil. 2014 Jan;93(1):17-28. doi: 10.1097/PHM.0000000000000011. PubMed 24355994 ↗
  • Wilson RD, Harris MA, Gunzler DD, Bennett ME, Chae J. Percutaneous peripheral nerve stimulation for chronic pain in subacromial impingement syndrome: a case series. Neuromodulation. 2014 Dec;17(8):771-6; discussion 776. doi: 10.1111/ner.12152. Epub 2014 Feb 11. PubMed 24512114 ↗
  • Wilson RD, Bennett ME, Nguyen VQC, Bock WC, O'Dell MW, Watanabe TK, Amundson RH, Hoyen HA, Chae J. Fully Implantable Peripheral Nerve Stimulation for Hemiplegic Shoulder Pain: A Multi-Site Case Series With Two-Year Follow-Up. Neuromodulation. 2018 Apr;21(3):290-295. doi: 10.1111/ner.12726. Epub 2017 Nov 22. PubMed 29164745 ↗
  • Gilmore CA, Ilfeld BM, Rosenow JM, Li S, Desai MJ, Hunter CW, Rauck RL, Nader A, Mak J, Cohen SP, Crosby ND, Boggs JW. Percutaneous 60-day peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-month follow-up of a randomized, double-blind, placebo-controlled trial. Reg Anesth Pain Med. 2019 Nov 17:rapm-2019-100937. doi: 10.1136/rapm-2019-100937. Online ahead of print. PubMed 31740443 ↗
  • Gilmore CA, Kapural L, McGee MJ, Boggs JW. Percutaneous Peripheral Nerve Stimulation for Chronic Low Back Pain: Prospective Case Series With 1 Year of Sustained Relief Following Short-Term Implant. Pain Pract. 2020 Mar;20(3):310-320. doi: 10.1111/papr.12856. Epub 2019 Dec 2. PubMed 31693791 ↗
  • Mainkar O, Solla CA, Chen G, Legler A, Gulati A. Pilot Study in Temporary Peripheral Nerve Stimulation in Oncologic Pain. Neuromodulation. 2020 Aug;23(6):819-826. doi: 10.1111/ner.13139. Epub 2020 Mar 17. PubMed 32185844 ↗
  • Deer TR, Eldabe S, Falowski SM, Huntoon MA, Staats PS, Cassar IR, Crosby ND, Boggs JW. Peripherally Induced Reconditioning of the Central Nervous System: A Proposed Mechanistic Theory for Sustained Relief of Chronic Pain with Percutaneous Peripheral Nerve Stimulation. J Pain Res. 2021 Mar 12;14:721-736. doi: 10.2147/JPR.S297091. eCollection 2021. PubMed 33737830 ↗
  • Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014 Oct;44(2):145-54. doi: 10.1016/j.semarthrit.2014.05.011. Epub 2014 May 14. PubMed 24928208 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jun 2024, 22 months.

Results were first posted in Nov 2026, 2 years 5 months after primary completion.

Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's 22 months is above that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2024 → Jun 2024, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Dec 14, 2022
StartActual
Jul 12, 2022
Primary completionActual
Jun 6, 2024
CompletionActual
Jun 6, 2024was Jul 2024
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Results
Results posted
posted Nov 6, 2026
Sites
1 site added, 1 site removed
Show site
  • International Spine Pain & Performance Center · Washington D.C., United States
Show 1 removed
  • International Spine Pain & Performance Center · Washington, United States
Nov 6, 2026
Start date
Jul 6, 2022→Jul 12, 2022
Nov 6, 2026
Study completion
Jul 2024→Jun 6, 2024 (actual)
Nov 6, 2026
Enrollment
20 (estimated)→3 (actual)
Nov 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Reduction in average pain and/or reduction in pain interferenceNow Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain IntensityTime frame: 3 months
Nov 6, 2026
Documents
Nov 6, 2026
Secondary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedChangesPercent Change in pain interferencePain Interference ScoreTime frame: 1 year → 3 months
  • EditedChanges in shoulder rangeShoulder Range of motionMotionTime frame: 1 year
  • RemovedChanges in pain intensityTime frame: 1 year
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Results posted
    Documents Study protocol ↗ posted
    1 site added, 1 site removed
    Show site
    • International Spine Pain & Performance Center · Washington D.C., United States
    Show 1 removed
    • International Spine Pain & Performance Center · Washington, United States
    Start date Jul 6, 2022→Jul 12, 2022
    Study completion Jul 2024→Jun 6, 2024 (now actual)
    Enrollment 20 (estimated)→3 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Reduction in average pain and/or reduction in pain interferenceNow Number of Subjects That Experienced ≥30% Reduction in Average Shoulder Pain IntensityTime frame: 3 months
    Secondary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedChangesPercent Change in pain interferencePain Interference ScoreTime frame: 1 year → 3 months
    • EditedChanges in shoulder rangeShoulder Range of motionMotionTime frame: 1 year
    • RemovedChanges in pain intensityTime frame: 1 year
    + 5 other changes: verification date, contact details, references, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05649917
Lead sponsor
International Spine, Pain and Performance Center
Responsible party
Mehul J. Desai (Study Principal Investigator, International Spine, Pain and Performance Center) — Principal investigator
First posted
Dec 14, 2022
Start date
Jul 12, 2022
Primary completion
Jun 6, 2024
Completion
Jun 6, 2024
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Study contacts

Mehul Desai, MD, MPH
principal investigator · International Spine Pain & Performance Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion